Futibatinib not checked

Taiho · TAS-120 · TAS-120 + fulvestrant

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 2 trial completes
Trials
9 active
15 in total · 9 in the EU
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
How it’s given
“TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.”In the company’s words, NCT04999761 on ClinicalTrials.gov
Tested for
Biliary Tract Cancer (2 trials), Advanced/Metastatic Cancer, Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer, Advanced Cholangiocarcinoma and 10 more
Main trialPhase 3
“To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer”In the company’s words, NCT07710885 on ClinicalTrials.gov
Other names
TAS-120 · TAS-120 + fulvestrant

Other drugs for Biliary Tract Cancer

All 78 drugs for Biliary Tract Cancer

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials15

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Apr 2030 Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Phase 2/3Active, not recruiting Apr 2027 Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Phase 2Active, not recruiting 1 Oct 2026 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Phase 2Recruiting Dec 2026 Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Phase 1Recruiting Jun 2027 AB122 Platform Study
Phase 3Terminated 22 Apr 2024 Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Phase 2Terminated 31 May 2023 A Study of TAS-120 in Patients With Metastatic Breast Cancer
Phase 2Terminated 8 Mar 2024 Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Phase 2Terminated 11 Nov 2024 Futibatinib in Patients With Specific FGFR Aberrations
Phase 1/2Completed 1 Oct 2020 A Study of TAS-120 in Patients With Advanced Solid Tumors
Phase 3Authorised not given SAFIR ABC10 : Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, platform phase 3 trial
Phase 2Authorised not given Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours
Phase 1/2Authorised not given AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 3Ended not given MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study
Phase 2Authorised not given FUTURE platform trial – A phase II platform trial of futibatinib in combination with (chemo)immunotherapy in colorectal cancer and other solid tumor entities
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Futibatinib

Following is part of Solo: you see every change to Futibatinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in